Member Info for Diversified

Based on the last fundraise, the share price rallied to an all time high prior to the distressed sale by Amphion.

Partnership agreements will also give this further momentum prior to the NDA submission and the 12 month milestone that follows.

Interesting tweet by Edward Roskill today reaffirming my belief that strategic partnerships are potentially imminent.

This in itself would be a good form of non-dilutive funding during a period of very low cash burn between now and approval.

‘Day traders should use patience to improve performance’

This is a very encouraging outcome. Like I said before, I don’t think Allis has finished building a position yet. His experience with Blue Earth Diagnostics is also a massive tick for me.

If ever big Pharma could facilitate a gas exchange that helped identify the function of the lung (unmet need) and the effectiveness of a vaccination against this current pandemic it’s now. #POLX would help meet this need.

Forecast a monthly cash burn of approx. 350k a month and a net cash balance at year end on the basis of a corporate partnership proving non dilutive funding.

I think a strategic partnership is pretty high on the agenda and the next catalyst for the share price that the market will be unable to price in, Unlike phase III results which will be priced in on the run up to FDA approval.

The next catalyst imo will be the NDA as I believe you could argue that the IP meets an unmet need and therefore possibly attains a priority review or at least provide a target date for the biggest catalyst in the companies history.

With the number of strategic opportunities available to the company which would increase its future pipeline, funding could easily be overcome. I am also not adverse to a small raise to create certainty.

After a 75% plus increase in the stock price over the last few weeks it comes as no surprise to see a bit of profit taking on relatively low volume. Friday’s large reported trade increased the strength on L2 with PLHC flip-flopping and contributing towards the rise.

Exciting times for a company with only a 35m odd market cap that has met the primary end point on Phase III trials and is facing a 40 year old comparatively inferior dangerous tech.

It has been up 75% odd over 4 weeks. I am relaxed and I will be taking advantage as and when I can.

https://m.youtube.com/watch?v=XNZKobVvJok

Video inbound. Both loaded and then removed within the last 30 mins.

https://www.proactiveinvestors.com/companies/news/911788/polarean-imaging-achieves-positive-phase-iii-results-in-two-clinical-trials-911788.html

Share register rebalanced

Fantastic results today, and while these results were expected the main news today is that the market seems to of filtered out some of the traders and profit takers which was really good to see. Too much hot money is not necessarily a good thing, a sustainable long term uptrend is far more appealing.

Funding

Recent director purchases would have provided a base to the current share price, as for Allis to have continued to build a sizable position in the company knowing the companies forward cash position, surely if a sizable placing was planned he could of just participated in that. It is also worth noting that the CEO has insisted in the past that the company cash burn is very little following the expensive phase III trial which should see the company through to approval.

Strategic partnerships

Today’s read out is a key milestone for the company to enable it to enter strategic partnerships which in itself would resolve any funding concerns.

NDA

Monday this week I contacted investor relations to help clarify priority FDA reviews and Hatch Waxman. I am waiting a response as it was implied that Richard was very busy this week and it may take a couple of days to reply.

Conclusion (in my opinion)

Imo something significant is being worked on in the background that has led the company directors to build on their own position in the free market. Allis will be only to aware of the potential of this company following the sale of Blue Earth D which means that he has unfinished business in building a more significant stake in POLX.

Relatively low forward cash burn enables the company to go into the next 18 months with a relatively clear path to market which can give current shareholders certainty about forward dilution. To consider a small raise would not be the end of the world but I think the company will naturally clarify its forward position in the not to distant future. NDA application, strategic partnerships and further sale of goods for research purposes (funding through grants, which enables the company to have a clear view of forward order book), will all contribute towards future funding and will be significant share price catalysts as it’s the unknowns that the market will struggle to price in. Between now and FDA approval, the free float will continue to shrink which will intensify and future forward moves.

I have seen many stocks that have seen a continuation of an upwards trend in anticipation of FDA approval over a longer period of time (STX) and also over a shorter period of time just before FDA results. I see no reason for this to be any different, other than the fact that this is a computer v computer which will help increase the probability of success. None of which is currently priced in, but prior to what could/should be FDA approval and commercialization would see a market cap in excess of £100m which in itself is a share price of 87p or a 270% increase.

"The use of conventional, anatomical MRI has, historically, not played a role in addressing the substantial unmet need in working up difficult-to-diagnose pulmonary diseases. The innovative approach we have taken with the use of hyperpolarized 129Xenon gas opens up a whole new window into how physicians diagnose, stage and monitor responses to treatment in a broad range of lung diseases with this high resolution, non-ionizing MRI method. Based on what has been demonstrated in these Clinical Trials, we are excited about the prospect of having the Company's technology available as an additional tool to potentially make a clinically significant impact in the future."

Would not be surprised to see a strong bounce in America from current market of -500. Overreaction.

Let the trend be your friend with the 30 day intraday chart showing a sustainable move forward imo. We need to see sustainable gains and an upwards trend.

If ever I have identified a 10/100 bagger before the event then this is it! Long term add and hold for me.

Here comes the big delayed chunky trade being filled.

I wonder if what appeared to be quite aggressive accumulation continues today. A £250k purchase at the days high is some conviction.

One thing is clear, the free float at stock is shrinking which will only add additional momentum.

At a £40m market cap I still consider this to be undervalued at anything less than £100m but at least the re-rating has begun.

Imo this goes to show how undervalued this continues to be as in addition to the read out I think we can expect some strategic partnerships in advance of FDA approval.

£38.9m market cap.

This has all the hallmarks of STX share price performance in 2019 imo. I for one will be here for the ups and downs.

After FDA approval and during receipt of commercial revenue.

Blue Earth Diagnostics employs approximately 100 people and is expected to generate revenues of $140M in the year to September 2019, primarily in the US.

Polx has a £36m market cap. By compassion Blue earth was sold for £342m. You can see the discrepancy that will narrow over time for a company with exposure to a larger market and is also looking at additional target markets through strategic partnerships.

‘We have begun early discussions with potential strategic partners in the pharmaceutical industry and in other geographic markets that could lead to important developments in new applications and uses for our technology, expansion into new territories, and which may bring economic benefits to the Group going forward.’

It’s these economic benefits that could fund the company through to FDA approval and beyond. With plenty of news in the hopper to continue to drive the company forward.

When considering the size of the market for Blue Earth for prostrate cancer it is expected to reach a global annual value of $12billion a year by 2025. Obviously as per POLX, Blue earth will absorb a proportion of the revenue from this market.

By comparison the target for POLX is $150billion with other target markets possible with their IP. This puts into consideration the prospective valuation of POLX when Blue earth was sold for $450m.

Mind blowing potential.